DAO — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL71474	0.58	9/20
SCHEMBL70493	0.67	7/20
SCHEMBL67365	0.47	6/20
SCHEMBL112135	0.32	6/20
Kojic Acid (SCHEMBL36895)	1.00	5/20
SCHEMBL121242	0.55	4/20
SCHEMBL124774	0.53	4/20
SCHEMBL70048	0.44	4/20
SCHEMBL8664	0.61	3/20
SCHEMBL10617	0.60	3/20
SCHEMBL49512	0.55	3/20
SCHEMBL49098	0.53	3/20
SCHEMBL69502	0.51	3/20
SCHEMBL77392	0.51	3/20
SCHEMBL22170	0.50	3/20
SCHEMBL66607	0.50	3/20
SCHEMBL65650	0.46	3/20
SCHEMBL66271	0.46	3/20
SCHEMBL121300	0.46	3/20
SCHEMBL40545	0.45	3/20

Clinical trials — most relevant to DAO by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Dietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy.	PHASE4	COMPLETED
A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)	PHASE3	COMPLETED
L-Arginine in Pre-Eclampsia	PHASE3	COMPLETED
Tryptophan MRI in People With Schizophrenia and Healthy Controls	PHASE2/PHASE3	COMPLETED
Sodium Benzoate for Treatment of Attenuated/Transient Psychosis. A Randomized Placebo-controlled Trial.	PHASE2	WITHDRAWN
Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease.	PHASE1/PHASE2	RECRUITING
Diclofenac Dose Response Study	PHASE1	RECRUITING
Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease	PHASE1	COMPLETED
iNOS With Positron Emission Tomography (PET) in Cellular Inflammation.	EARLY_PHASE1	COMPLETED
Prevalence of DAO (diamino Oxidase) Deficiency in Newborns	nan	COMPLETED
Vancomycin Associated Red Man Syndrome (RMS)	nan	COMPLETED
Effect of Low Histamine-Based Modified Mediterranean Diet in Multiple Sclerosis	nan	COMPLETED
Genetic DAO Deficiency and Lower Urinary Tract Symptoms	nan	COMPLETED
Requirement for Leucine in Adults Over 60 Years	nan	COMPLETED
Lysine Requirement of Elderly Men and Women Over 60 Years of Age	nan	COMPLETED
In Vivo Assessment of Histamine Pharmacodynamics	nan	WITHDRAWN
Indicator Amino Acid Oxidation in ICU Patients	nan	COMPLETED
Phenylalanine Requirement of Adults >65 Years.	nan	COMPLETED
TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke	nan	COMPLETED
Prevalence of High Plasmatic 3OMethyldopa Level in a Specific Population of Patients With a Symptomatology Compatible With AADC Deficiency	nan	UNKNOWN
Leucine Requirements in School-Age Children	nan	NOT_YET_RECRUITING
Leucine Requirements During Pregnancy	nan	RECRUITING
Protein Requirements for Active Children	nan	COMPLETED
L-arginine add-on Therapy in Patients With Schizophrenia	nan	COMPLETED
The Clinical Value of the Nitric Oxide System Components in Asthma and COPD	nan	UNKNOWN
Protein Requirements in Resistance Trained Females	nan	COMPLETED
Sulphur Amino Acid Requirements in Adults >60 Years	nan	COMPLETED
Protein Requirements After Bariatric Surgery	nan	RECRUITING
Protein Requirement During Lactation	nan	COMPLETED
PKU Protein Requirements	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a DAO binder may also engage these)

Protein	Name	Similarity
P00371	—	1.000	P00371 →
A2V9Y8	—	1.000	A2V9Y8 →
P18894	—	1.000	P18894 →
O35078	—	0.998	O35078 →
Q9Z1M5	—	0.998	Q9Z1M5 →
P22942	—	0.997	P22942 →
Q9HGY3	—	0.995	Q9HGY3 →
Q9Z302	—	0.995	Q9Z302 →
Q95XG9	—	0.995	Q95XG9 →
C4R6B0	—	0.994	C4R6B0 →
Q556W1	—	0.993	Q556W1 →
Q9Y7N4	—	0.993	Q9Y7N4 →
Q19564	—	0.992	Q19564 →
P24552	—	0.991	P24552 →
A0A7E6FSU6	—	0.990	A0A7E6FSU6 →
C0HMB0	—	0.989	C0HMB0 →
C4R4G9	—	0.989	C4R4G9 →
O01739	—	0.989	O01739 →
Q99042	—	0.988	Q99042 →
A8WXM1	—	0.988	A8WXM1 →
P80324	—	0.988	P80324 →
Q10058	—	0.988	Q10058 →
Q4WAZ0	—	0.988	Q4WAZ0 →
O43029	—	0.988	O43029 →
A8XJ44	—	0.987	A8XJ44 →
P78875	—	0.986	P78875 →
A0A095CCB2	—	0.986	A0A095CCB2 →
J9VPE7	—	0.985	J9VPE7 →
A0A7R7WPS5	—	0.985	A0A7R7WPS5 →
T2HG31	—	0.984	T2HG31 →